Literature DB >> 10704734

Biochemical mechanism of cross-resistance to paclitaxel in a mitomycin c-resistant human bladder cancer cell line.

R J Bleicher1, H Xia, H A Zaren, S V Singh.   

Abstract

9-fold more resistant to mitomycin C (MMC) than parental cells (J82/WT). The IC(50) values for paclitaxel in J82/WT and J82/MMC-2 cell lines were 0.7+/-0.03 and 2.8+/-0.7 microM, respectively (P<0. 05). Thus, the J82/MMC-2 cell line exhibited 4-fold cross-resistance to paclitaxel compared with J82/WT. Intracellular accumulation of [(3)H]paclitaxel was comparable in J82/WT and J82/MMC-2 cell lines. There were no qualitative or quantitative differences between the J82/WT and J82/MMC-2 cell lines in terms of their alpha-tubulin and beta-tubulin contents. Paclitaxel-induced apoptosis could not be detected in either cell line over a wide range of drug concentrations. These results indicate that cross-resistance to paclitaxel in the J82/MMC-2 cell line is not linked to reduced drug accumulation, increased drug efflux, alterations in tubulin content or reduced paclitaxel-induced apoptosis. Paclitaxel-induced DNA strand breakage, however, determined by alkaline elution, was markedly lower in the J82/MMC-2 cell line than in J82/WT. These results suggest that paclitaxel cross-resistance in J82/MMC-2 may be attributed to reduced paclitaxel-induced DNA strand breakage. The precise mechanism of reduced paclitaxel-induced DNA strand breakage in J82/MMC-2 cell line relative to J82/WT cells, however, remains to be elucidated.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10704734     DOI: 10.1016/s0304-3835(99)00365-1

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  1 in total

1.  Deficiency in SNM1 abolishes an early mitotic checkpoint induced by spindle stress.

Authors:  Shamima Akhter; Christopher T Richie; Jian Min Deng; Eric Brey; Xiaoshan Zhang; Charles Patrick; Richard R Behringer; Randy J Legerski
Journal:  Mol Cell Biol       Date:  2004-12       Impact factor: 4.272

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.